Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.59 |
| ▸ | ARG2 | P78540 | 5/20 | 0.53 |
| ▸ | ARG1 | P05089 | 3/20 | 0.53 |
| ▸ | NOS2 | P35228 | 6/20 | 0.47 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17262412 | 1.00 | GSR (0.59) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL259006 | 1.00 | GSR (0.59) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL29958570 | 0.98 | GSR (0.57) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL2599185 | 0.98 | GSR (0.57) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL79859 | 0.93 | GSR (0.56) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL2722969 | 0.93 | GSR (0.56) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL198242 | 0.93 | GSR (0.56) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL30463729 | 0.91 | GSR (0.54) | GSRARG2ARG1NOS2NOS1 | |
| Lysine SCHEMBL4956653 | 0.88 | GSR (0.74) | GSRARG2ARG1NOS2NOS1 | |
| Ornithine SCHEMBL10560893 | 0.86 | GSR (0.64) | GSRARG2ARG1NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006841-A2 | COMPOSITIONS FOR WEIGHT LOSS AND CANCER TREATMENT | KNOWLEDGE PHARMACEUTICALS INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20220296584-A1 | Membrane Active Molecules | KNOWLEDGE PHARMACEUTICALS INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3973997-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | KNOWLEDGE PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | disclosed |
| EP-3615084-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018200412-A1 | MEMBRANE ACTIVE MOLECULES | BraneQuest, Inc. (US) | 2018-11-01 | — | — | WO | disclosed |
| US-20180303821-A1 | MEMBRANE ACTIVE MOLECULES | KNOWLEDGE PHARMACEUTICALS INC. | 2018-10-25 | — | — | US | disclosed |
| US-20170369914-A1 | METHODS OF PRODUCING 6-CARBON CHEMICALS USING 2,6-DIAMINOPIMELATE AS PRECURSOR TO 2-AMINOPIMELATE | INVISTA NORTH AMERICA S.A.R.L. | 2017-12-28 | — | — | US | disclosed |
| US-9745607-B2 | Methods of producing 6-carbon chemicals using 2,6-diaminopimelate as precursor to 2-aminopimelate | INVISTA NORTH AMERICA S.A.R.L. (US) | 2017-08-29 | — | — | US | disclosed |
| EP-3143152-A1 | METHODS OF PRODUCING 6-CARBON CHEMICALS USING 2,6-DIAMINOPIMELATE AS PRECURSOR TO 2-AMINOPIMELATE | Invista Technologies S.à r.l. (CH) | 2017-03-22 | — | — | EP | disclosed |
| US-20150361462-A1 | METHODS OF PRODUCING 6-CARBON CHEMICALS USING 2,6-DIAMINOPIMELATE AS PRECURSOR TO 2-AMINOPIMELATE | INV NYLON CHEMICALS AMERICAS, LLC | 2015-12-17 | — | — | US | disclosed |
| WO-2015176026-A1 | METHODS OF PRODUCING 6-CARBON CHEMICALS USING 2,6-DIAMINOPIMELATE AS PRECURSOR TO 2-AMINOPIMELATE | Invista North America S.á.r.l. (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2010046713-A2 | METHODS FOR PREPARING HETEROCYCLIC RINGS | ISIS INNOVATION (GB) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046713-A2 | METHODS FOR PREPARING HETEROCYCLIC RINGS | ISIS INNOVATION (GB) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296584-A1 | Membrane Active Molecules | GABRP, GRIN3A, GRIN2A | GSR 869/4885ARG2 2061/4885ARG1 4334/4885 |
| US-20180303821-A1 | MEMBRANE ACTIVE MOLECULES | GABRP, GRIN3A, GRIN2A | GSR 869/4885ARG2 2061/4885ARG1 4334/4885 |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | GABRP, GRIN3A, GRIN2A | GSR 869/4885ARG2 2061/4885ARG1 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.